Wolfe, Frederick

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet

Global Health and EpidemiologyHealth Systems, Economic Evaluations, Quality of Life

Cited by 8,888

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet

Global Health and EpidemiologyHealth Systems, Economic Evaluations, Quality of Life

Cited by 8,291

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

Clegg, D. O., Reda, D. J., Harris, C. L., Klein, M. A., O'Dell, J. R., Hooper, M. M., Bradley, J. D., Bingham, C. O., Weisman, M. H., Jackson, C. G., et al. (2006) · New England Journal of Medicine

Osteoarthritis Treatment and MechanismsMusculoskeletal pain and rehabilitation

Cited by 1,329

Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis

Pincus, T., Olsen, N. J., Russell, I. J., Wolfe, F., Robert Harris, E., Schnitzer, T. J., Boccagno, J. A., & Krantz, S. B. (1990) · The American Journal of Medicine

Erythropoietin and Anemia TreatmentBiosimilars and Bioanalytical Methods

Cited by 226

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

Aletaha, D., Landewe, R., Karonitsch, T., Bathon, J., Boers, M., Bombardier, C., Bombardieri, S., Choi, H., Combe, B., Dougados, M., et al. (2008) · Arthritis Care & Research

Rheumatoid Arthritis Research and TherapiesStatistical Methods in Clinical Trials

Cited by 214

An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial

Pincus, T., Strand, V., Koch, G., Amara, I., Crawford, B., Wolfe, F., Cohen, S., & Felson, D. (2003) · Arthritis & Rheumatism

Rheumatoid Arthritis Research and TherapiesStatistical Methods in Clinical Trials

Cited by 146